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1 
Coronary artery disease is an important complication of diabetes mellitus I之 Inthe 
genera1 popu1ation， the concentrations of tota1 cho1estero1 and 10w-density lipoprotein 
(LOL) are positive1y associated with the preva1ence of coronary heart disease3). It is 
well known that hyperlipidemia as a metabolic abnorma1ity is frequently associated with dト
abetes4-7).τhese suggest that coronary heart disease in the diabetic is partly re1ated to ab-
norma1ities of lipid metabo1ism. Unlike the microvascu1ar comp1ications which occur 
more frequently in 100M， the macrovascu1ar comp1ications are more frequently observed 
in NIOOM. Thus the treatment of abnorma1ities of lipid metabo1ism in NIOOM may 
reduce the rates of morbidity and morta1ity from arteriovascular disease. Probuco1， a 
cholestero1-10wering agent with uncertain mode of action， and pravastatin， an inhibitor of 
the rate-1imiting enzyme of cho1estero1 biosynthesis， 3-hydroxy-3-methy1g1utaryl coenzyme 
A (HMG-CoA) reductase， are now used frequently to treat hypercholesterolemia. However， 
the effect of these drugs on lipid metabolism in diabetic patients with hypercholesterolemia 
remains to be fully elucidated. In the present study， the effect of smaIl doses of probuco1 
and pravastatin on concentrations of serum lipids and apolipoproteins was investigated in 
non司obeseNIOOM patients (frequently observed in Japan) with hypercho1esterolemia. 
Subject s and methods 
Subjects 
Thirty subjects of NIOOM with hypercholesterolemia (above 240mgjd1) were selected 
and divided randomly into two groups. The patients were hypercho1estero1emic despite 
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of being received low fat and low cholesterol diet. The diabetes was stable prior to entry 
into the study. One group of fifteen patients (ten type I a and five type I b hyperlipide-
mia) were administered probucol (250mg twice a day) and the other group of fifteen pa-
tients (ten type IIa and five type IIb hyperlipidemia) were administered pravastatin (5mg 
twice a day) for twelve months. They have not been taken any drugs to lower plasma 
lipid concentrations. Patients with evidence of abnormal hepatic or renal function and a 
history of excessive ethanol consumption were excluded. Quality of diet and dose of in-
sulin or oral hypoglycemic agents (OHA) were not changed during the study. The ve-
nous blood sample was taken after a 12-14 hr fast， and concentrations of serum lipids and 
apolipoproteins were measured. Determinations of blood cel count， serum creatinine， 
blood urea nitrogen， transaminases， creatine phosphokinase， alkaline phosphatase and lac同
tic dehydrogenase were performed at each blood sampling. No adverse drug experiences 
were reported. Besides， no drug-related side effect was revealed in clinical and laboratory 
examinations. Clinical characteristics of diabetic subjects were shown in Table 1. 
Measurements 
The percentages of the HbA 1 and HbA 1 c ontents were measured by affinity chro-
matography (normal ranges， HbA 1 6-8 % and HbA 1 c 4-6 %). Serum total cholesterol8) 
and triglyceride9) were determined enzymatically. HDL cholesterol was determined by 
measurement of the lipid in the supernatant after precipitation of VLDL and LDL in 1 ml 
of serum with 50μ1 of 2moljl MnCl2 and 50μ1 of sodium heparin. Apolipoproteins were 
measured by immuno-nephelometry using the commercially available kit of Daiichi Chem-
ical Pharmaceutical Co.， Tokyo. Intraassay coefficients of variation were 4-8 % for 
apolipoproteins. Friedewald equation was used for calculation of LDL cholesterol. 
Statistical analyses 
Analysis of variance， non四parametricstatistics and two-tailed Student's non-paired t 
test were used for statistical analyses， The data are expressed as the mean 土 SD.
Results 
Clinical characteristics in NIDDM patients 
As shown in Table 1， NIDDM subjects were similar intheir clinical characteristics 
before probucol or pravastatin treatment. BMI was not changed during the study in 
either group. 
Changes in serum l.伊idconcentrations 
As shown in Table 2， the concentrations of serum lipids were similar before probucol 
or pravastatin treatment. Treatment with probucol or pravastatin resulted in a signifi-
cant decrease in plasma total and LDL cholesterol concentrations after six months， and 
the decrease remained til twelve months. HDL cholesterol was significantly reduced by 
probucol treatment after twelve months. Triglyceride levels were not altered in either 
group. 
Changes in serum apolipoprotein concentrations 
Apolipoprotein B (apo-B) concentrations were significantly decreased by probucol or 
pravastatin treatment. Serum apo幽Elevel was significantly decreased by pravastatin treat-
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Table 1 Clinical characteriscs of subjects 
probucol-treated pravastatin-treated 
Mean age (years) 58 + 12 56士 11
Sex ratio (f: m) 10 5 10 5 
duration of 
diabetes (years) 14.1士 5.7 12.5土 5.1
Treatment 
insulin 5/15 6//15 
tablets 5/15 5/15 
diet only 5/15 4/15 
FBG (mgjdl) 144士 28 147士 32
HbA1 ( %) 10.0土1.5 9.8 + 1.5 
HbA1 C (%) 7.7 + 1.2 7.7土1.2
BMI (kgjm2) 17.6 + 2.6 18.6土 4.4
complications 
neuropathy 9/15 10/15 
retinopathy 6/15 6/15 
nephropathy 3/15 2/15 
The values are expressed as mean :t SD. The number of subjects in each group was 
fifteen 
FBG : fasting blood glucose， BMI: body mass index (kgjm2). 
Clinical characteristics were not different from each other before probucoト andpra-
vastatm-treatment. 
ment. Serum levels of apo-AI ， AII， CII and CIII were not significantly altered in either 
group. 
Changes in various indices 
The ratio of apo-A 1 to apo-AII was not altered in either group. The ratio of apo-B 
to apo-A 1 was significantly decreased by pravastatin treatment. The ratio of HDL chol-
esterol to apo-A 1 was slightly decreased by probucol treatment but slightly increased by 
pravastatin treatment. Consequently， atsix or twelve months after the treatment， the ra田
tio of HDL cholesterol to apo-A 1 in pravastatin-treated group was significantly higher 
than that in probucol-treated group. The ratio of the difference between total and HDL 
cholesterol to HDL cholesterol was significantly decreased by pravastatin treatment， 
though not changed by probucol treatment. 
Changes仇glycemiccontrol 
Glycosylated hemoglobin concentration was not changed during the study in either 
group. 
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Table 2 Changes in serum lipids and apolipoproteins concentrations after treatment 
T. ch 
TG 
HDL 
LDL 
apoproteIn 
AI 
AII 
B 
CII 
Cm 
E 
γ. ch-HDL 
日DL 
AI/AII 
B /A 1 
HDL/A 1 
LDL/B 
HbA， 
HbA，c 
probucoI treatment 
before 6 months 12 months 
300士40 247土44**
150:171 146士60
53士19 41:1 16 
217土47 177土45*
128:128 114土23
31.8土7.4 26.8:13.5 
189士44 143土58*
4.8土1.5 4.3:12.4 
13.0:18.3 11.5土6.0
6.0土2.1 5.8土1.9
4.7:12.8 5.0土2.3
4.4土0.8 4.3土0.8
1.5ごと0.5 1.3土0.5
0.41土0.070.36:10.10#
1.15ごと0.26 1.24土0.46
10.0土1.5 10.4士1.8
7.7:1:1.2 7.9土1.4
245土45**
143:160 
38土16*
178士43*
110土25
27.0:13.6 
140士60*
4.4:1:2.0 
11.8士6.2
5.8:12.0 
5.4士2.5
4.1土0.7
1.3土0.3
0.35土0.08~ 
1.27こと0.34
10.4:1 1.8 
7.8:1:1.3 
pravastatIn treatment 
before 6 months 12 months 
295土33 243土37**
153土87 147:154 
48:1 13 51:1 1 
201土38 153:131** 
113:133 115土16
31.3土8.7 27.2士4.8
162:161 111:123* 
5.8:1 1. 7 4.6:1 1.6 
12. 7:1 4 . 0 1 . 9土2.8
6.1土2.1 4.4士1.6* 
5.1:12.1 3.8:1 1.4 * 
4.2ごと1.0 4.'2ごと0.7
1.4:10.6 1.0土0.2* 
0.42こと0.05 0.44ごと0.07#
1.24:10.45 1.38:10.18 
9.8土1.5 10.4土1.8
7.7:1:1.2 7.9:1:1.4 
231:136** 
147:152 
50土10
145:133** 
114土18
28.0土4.9
108土26
5.0:1 1. 7 
12.0土3.1
4.5土1.5
3.6土1.3* 
4.1:10.8 
0.9:10.2* 
0.44土0.06~ 
1.34:10.20 
10.2土1.6
7.9:1:1.3 
T. ch : total cholesterol， TG : triglyceride. The values are expressed as mean :t SD. 
The number of subjects in each group was fifteen. * pく0.05， ** Pく0.02，
significant1y different from that before treatment. #嗣#and ~-~ pく0.05，signifi-
cantly different from each other. 
Discussion 
Non-obese NIDDM patients were selected in this study， because non-obese NIDDM 
is frequent in Japan， and obesity itself， rather than diabetes mellitus， has an important role 
in abnormality of lipid metabolism. Probucol and pravastatin treatments similarly d。
::reased serum total and LDL cholesterol levels， suggesting that these drugs are useful for 
the treatment of hypercholesterolemia in NIDDM patients. There have been no reports 
regarding the influence of the mode of diabetic therapy on the cholesterol-lowering effect 
of probucol or pravastatin. Although the number of subjects was too small to say clearly 
in the present study， probucol or pravastatin exhibited similar cholesterol-lowering effects 
in diet個， OHA-and insulin胸treatedNIDDM. It has been reported that therapy with in-
hibitors of HMG四CoAreductase was associated with a 20-30 % decrease in the plasma 
concentration of triglyceride in hypercholesterolemic patientsIO-12) and in NIDDM 
patients 13，14). However， serum triglyceride levels were not significant1y changed atter 
lkeda T et al 5 
treatment in either group probably because non-obese NIDDM patients had relatively low 
serum levels of triglyceride in the present study. Probucol has been reported to decrease 
HDL cholesterol in fami1ial hypercholesterolemia 15-18). In the present study， HDL cho四
lesterol concentrations were significant1y decreased by probucol treatment. This result 
was in agreement with the report of Hattori et ai.， which showed a significant reduction 
in HDL-cholesterol level by probucol treatment in NIDDM patients 19). Therefore， pro-
bucol effect on HDL-cholesterol may be similar in fami1ial hypercholestrolemia and 
NIDDM patients. Serum levels of apo-B were significant1y decreased by probucol or 
pravastatin treatment. Because it has been suggested that apo品 maybe a better predic-
tive factor than lipids for coronary heart disease20，21)ラ probucolor pravastatin treatment 
may reduce coronary heart disease in NIDDM. Although Yoshino et a1.14) have reported 
that apかA1 level was significant1y increased by pravastatin treatment in NIDDM pa-
tients after 12 months， apo-A 1 level was not altered in the present study. One of the 
reasons for this discrepancy may be that HbA 1 c concentration after treatment was 
s1ight1y decreased in their NIDDM patients， while it remained constant in our treatment. 
Serum apo同Econcentration was significant1y decreased by prιvastatin treatment. This 
result was in agreement with the report of Yoshino et a1.14). Pravastatin treatment may 
enhance the rate of metabo1ic c1earance of chylomicron remnant. 
The ratio of apo同Bto apo・A1 has been suggested as a helpful parameter for assess-
ing the relative risk of coronary heart disease22). This ratio and the ratio of the differ-
ence between total and HDL cholesterol to HDL cholesterol， atherogenic indices， were 
significant1y decreased by pravastatin treatment， but not by probucol treatment. There-
fore， pravastatin， rather than probucol， may be more useful for the treatment of hyper-
cholesterolemia associated with NIDDM. Interestingly， the ratio of HDL cholesterol to 
apo-A 1 after treatment was significant1y different between probucol-treated and prava-
statin同treatedgroup， suggesting that composition of HDL cholesterol may be different 
between probucol treatment and pravastatin treatment. Because HDL cholesterol has 
been suggested to have a protective effect on atherosc1erosis23，24)ラ th
Summary 
To elucidate the effect of small doses of probucol and pravastatin on serum conceル
trations of 1ipids and apolipoproteins in hypercholesterolemic patients (above 240 mg/dl) 
associated with non-obese non-insu1in dependent diabetes mellitus (NIDDM)， comparison 
was made between fifteen subjects treated with probucol (250mg twice a day) and fifteen 
subjects treated with pravastatin (5mg twice a day) for twelve months. Serum levels of 
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total cholesterol (from 300土 40to 245土 45mgjdl and from 295土 33to 231 :t 36 
mgjdl， mean土 SD)，LDL-cholesterol (from 217 + 47 to 178土 43mgj dl and from 201 
+ 38 to 145土 33mgjdl)， and apolipoprotein B (apo-B， from 189 + 44 to 140 + 60 
mgj dl and from 162土 61 to 108 + 26 mgjdl) were significantly decreased in the 
probucol-and pravastatirトtreatedgroups， respectively. Glycosylated hemoglobin concen-
trations were not altered during the study in either group， and clinical and laboratory ex-
aminations did not reveal any drug幅relatedside effect during the study. We conclude 
that small doses of probucol or pravastatin may be useful for the treatment of hyper-
cholesterolemia associated with non-obese NIDDM patients. 
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